Edwards Lifesciences Logo
US28176E1082
936853
EW

Edwards Lifesciences

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 98,89 € (+2,79%). La mediana è 100,07 € (+4,01%).

Acquista
  34
Mantieni
  15
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • CMS guideline on TAVR reimbursement strengthens Edwards Lifesciences

    US agency CMS has published a final national reimbursement guideline for TAVR that also provides reimbursement for asymptomatic aortic stenosis, thereby strengthening the TAVR market. Stifel views the decision as positive for Edwards Lifesciences and expects it to support the long-term revenue growth forecast of over 10%. The guideline retains case volume requirements and the role of the heart team including cardiac surgeons, but allows asynchronous chart review and requires only a single TAVR operator in the room, which increases procedural efficiency. CMS also announced a national review of reimbursement for TAVR in aortic regurgitation, expected to conclude on June 8, 2027. » Altro su de.investing.com


  • Edwards Lifesciences noted as leader in TAVR growth by Aristotle Value fund

    Aristotle Capital's Value Equity Fund highlighted Edwards Lifesciences for its leadership in transcatheter aortic valve replacement (TAVR) and structural heart therapies, citing the procedure's role in expanding patient eligibility and market adoption. The fund referenced Edwards' market position and recent stock range, with shares around $90.78 and a market cap near $51.8 billion. The mention came in the fund's Q2 2026 letter, which contrasted its own underperformance versus AI-driven index gains while still listing Edwards among notable holdings. 68 hedge funds held Edwards at the end of Q1 2026, up from 64 the prior quarter. » Altro su finance.yahoo.com


  • Edwards Lifesciences reaches new 52-week high at 92.94 USD

    Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » Altro su de.investing.com


  • Edwards Lifesciences hits 52-week high of $87.89 after strong Q1

    Edwards Lifesciences shares rose to a 52-week high of $87.89 and are currently trading at $87.91. In Q1 2026 the company reported revenue of $1.65bn (+12.7% currency‑adjusted) and earnings per share of $0.78, both above expectations. Analysts revised their views: several firms raised price targets and ratings, while InvestingPro rates the stock as overvalued and several earnings forecasts were revised down. Theodora Mistras was also appointed as the new chief financial officer effective late May. » Altro su de.investing.com


  • Edwards Lifesciences names Doretta Mistras chief financial officer

    Edwards Lifesciences has appointed Doretta Mistras as corporate vice president and CFO; she will assume the role at the end of May and succeeds Scott Ullem, who had already announced his departure and will remain as a strategic adviser during the transition. Mistras joins from Viatris, where she had served since March 2024 as CFO of the global finance organization and previously held leadership roles in healthcare investment banking at Citigroup and Goldman Sachs. The company has a market capitalization of $48 billion, revenue growth of 14% and a gross profit margin of nearly 78%; the stock is trading near its 52-week high. Analysts have recently cut their earnings forecasts (13 analysts), giving the CFO change added significance. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Edwards Lifesciences ha registrato ricavi pari a 1,51 Mld € e un utile netto di 271,48 Mln €
(EUR) settembre 2026
YoY
Ricavi 1,51 Mld 14,44%
Utile lordo 1,19 Mld 15,31%
Utile netto 271,48 Mln 9,44%
EBITDA 360,29 Mln 9,08%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
56,05 Mld €
Numero di azioni
575 Mln
Massimo/minimo a 52 settimane
97,97 € - 67,92 €
Dividendi No
Beta
0,83
Rapporto P/E
60,54
Rapporto PEG
-2,52
Rapporto P/B
5,69
Rapporto P/S
9,23

Profilo aziendale

Edwards Lifesciences Corporation fornisce prodotti e tecnologie per le malattie strutturali del cuore e per la terapia intensiva e il monitoraggio chirurgico negli Stati Uniti, in Europa, in Giappone e a livello internazionale. Offre prodotti per la sostituzione transcatetere delle valvole cardiache per la sostituzione mini-invasiva delle valvole cardiache; e prodotti per la riparazione e la sostituzione transcatetere delle valvole cardiache per il trattamento delle malattie delle valvole mitrale e tricuspide. La società fornisce inoltre i sistemi di riparazione valvolare transcatetere PASCAL e Cardioband per la terapia mini-invasiva. Inoltre, offre soluzioni strutturali cardiache chirurgiche, come la valvola aortica chirurgica sotto il nome INSPIRIS; KONECT RESILIA, un condotto valvolato aortico in tessuto preassemblato per pazienti che necessitano della sostituzione della valvola, della radice e dell'aorta ascendente; e HARPOON Beating Heart Mitral Valve Repair System per pazienti con rigurgito mitralico degenerativo. Inoltre, la società fornisce soluzioni per la terapia intensiva, tra cui sistemi avanzati di monitoraggio emodinamico per misurare la funzione cardiaca e lo stato dei fluidi del paziente in ambito chirurgico e di terapia intensiva; e il software Acumen Hypotension Prediction Index, che avvisa i clinici in anticipo quando un paziente sviluppa una pressione arteriosa pericolosamente bassa. La società distribuisce i suoi prodotti tramite una forza vendita diretta e distributori indipendenti. Edwards Lifesciences Corporation è stata fondata nel 1958 e ha sede a Irvine, in California.

Nome
Edwards Lifesciences
CEO
Bernard J. Zovighian
Sede centrale Irvine, ca
Stati Uniti
Sito web
Settore
Sanità
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
27/03/2000
Dipendenti 16.000

Simboli di borsa

Borsa Simbolo
NYSE
EW
XETRA
EWL.DE
Frankfurt
EWL.F
Düsseldorf
EWL.DU
Milan
1EW.MI
London
0REN.L
SIX
EW.SW
München
EWL.MU
Wien
EWLS.VI
🍪

Parqet  usa i cookie. Scopri di più